Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 7/30 cls
AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) Baird Christopher Raymond Downgrade Neutral (from market outperform) -17% $31.48
Leerink Joseph Schwartz Price target Market outperform
Raymond also lowered his target to $36 from $40 after AMAG's management said in its 2Q10 earnings call that it believes Feraheme ferumoxytol will likely play "a smaller role" in dialysis due to a CMS final rule establishing a bundled payment rate for dialysis services administered

Read the full 1016 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE